Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Why PD-L1 expression varies between studies of lung cancer: results from a Bayesian meta-analysis.

Scientific reports - 4 Feb 2025

Ngo Preston, Cooper Wendy A, Wade Stephen, Fong Kwun M, Canfell Karen, Karikios Deme, Weber Marianne

Abstract excerpt

PD-L1 expression is an important biomarker for the management of non-small cell lung cancer (NSCLC) but has been highly heterogeneous across studies. We developed a statistical model to reconcile conflicting estimates of PD-L1 prevalence by accounting for between-study variation in test sensitivity, specimen age, and laboratory count. In doing so, we obtained refined estimates for PD-L1 expression prevalence and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to B7-H1 Antigen
Share to Bayes Theorem

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers, Tumor

Share to Carcinoma, Non-Small-Cell Lung

Share to Gene Expression Regulation, Neoplastic

Share to ROS1 gene

Share to Lung Neoplasms

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 39905106
DOI: 10.1038/s41598-024-80301-9
PMCID: PMC11794894

Genes

ALK
EGFR
KRAS
MET
RET
ROS1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Why PD-L1 expression varies between studies of lung cancer: results from a Bayesian meta-analysis.PMID 39905106Read ↗

Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer.Semantic proximity Read ↗

PD-L1 expression in patients with non-small-cell lung cancer is associated with sex and genetic alterations: A retrospective study within the Caucasian population.Semantic proximity Read ↗

Temporal Effect on PD-L1 Detection and Novel Insights Into Its Clinical Implications in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Programmed Death Ligand-1 and Tumor Mutation Burden Testing of Patients With Lung Cancer for Selection of Immune Checkpoint Inhibitor Therapies: Guideline From the College of American Pathologists, Association for Molecular Pathology, International Association for the Study of Lung Cancer, Pulmonary Pathology Society, and LUNGevity Foundation.Semantic proximity Read ↗

PD-L1 Expression by RNA-Sequencing in Non-Small Cell Lung Cancer: Concordance with Immunohistochemistry and Associations with Pembrolizumab Treatment OutcomesSemantic proximity Read ↗

Landscape of Biomarkers in Non-small Cell Lung Cancer Using Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry.Semantic proximity Read ↗

Unraveling the nexus: Tumor mutational burden, PD-L1 expression, and oncogenic alterations in non-small cell lung cancer cytology specimens.Semantic proximity Read ↗

The Correlation Among PD-L1 Expression and the Driver Genes Status in Malignant Pleural Effusion of Lung Adenocarcinoma.Semantic proximity Read ↗

Profiling non-small cell lung cancer reveals that PD-L1 is associated with wild type EGFR and vascular invasion, and immunohistochemistry quantification of PD-L1 correlates weakly with RT-qPCR.Semantic proximity Read ↗

Clinicopathological and molecular characteristics associated with PD-L1 expression in non-small cell lung cancer: a large-scale, multi-center, real-world study in China.Semantic proximity Read ↗

Agreement between PDL1 immunohistochemistry assays and polymerase chain reaction in non-small cell lung cancer: CLOVER comparison studySemantic proximity Read ↗

PD-L1 status on Circulating Tumor Cells: A Promising Predictor in Advanced Lung Cancer with PD-1/PD-L1 immunotherapiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.